iCo-008

MedImmune Cambridge-derived Clinical Development
Partners	Product	Target	Disease	PreC	PhI	PhII	PhIII	Fld	Mkt
iCo	iCo-008	eotaxin₁	allergic conjuntivitis

iCo-008 is a human monoclonal antibody that acts to specifically neutralise the protein eotaxin1. iCo-008 was discovered and developed by Cambridge Antibody Technology and is licensed to iCo Therapeutics for further development and commercialisation.

iCo-008 targets eotaxin₁, a member of the chemokine family of proteins that acts as messenger molecules between the cells of the immune system. During an allergic response the levels of eotaxin₁ are elevated. This attracts eosinophils, a type of white blood cell, into tissues where they can degranulate causing tissue damage that occurs in a variety of allergic disorders.

Phase I/II studies of iCo-008 in patients with severe allergic disorders have been completed and iCo-008 was found to be safe and well-tolerated. iCo Therapeutics plans to develop iCo-008 initially for the treatment of ocular allergies including Vernal Keratoconjunctivitis (VKC), a severe ocular allergy that may pose a threat to vision.